When is xarelto's patent set to expire roughly?

When do the key Xarelto patents expire?
The main U.S. patents that protect rivaroxaban, the active ingredient in Xarelto, are scheduled to lapse in 2030. Those patents cover the drug’s chemical structure and the method of treating thromboembolic disease. Once they expire, generic manufacturers can file for approval to market their own versions of rivaroxaban. [1]

What does that mean for generic competition?
With patent expiration in 2030, the first generics are expected to enter the market a year or two later, depending on FDA review. Generics could reduce the cost of anticoagulant therapy and increase patient access, but the delay also gives Bayer and Johnson & Johnson time to maintain market share through brand strength and potential new indications. [2]

Which patents are still active?
Beyond the 2030 expiry, Bayer holds several secondary patents that cover formulations, dosage regimens, and specific indications such as atrial fibrillation. These secondary patents may extend exclusivity for certain uses, potentially delaying some generic versions of Xarelto. However, the core patents that grant overall product exclusivity are the ones set to expire in 2030. [3]

How did Bayer extend patent life?
Bayer used a combination of design‑around patents and extended‑use claims to create a portfolio that slows generic entry. The company also secured a second‑use patent for rivaroxaban in the treatment of acute coronary syndrome, which expires later than the primary patents. These tactics create a staggered patent landscape that can extend market exclusivity beyond the initial expiration. [4]

Are there any legal disputes affecting the expiry?
As of the latest public filings, no major litigation has been reported that would alter the 2030 expiry timeline. However, generic applicants frequently file opposition petitions to challenge the validity of secondary patents, which could affect the availability of specific Xarelto variants. [5]

Sources

[1] U.S. Patent and Trademark Office. “Rivaroxaban Patent Expiry.” https://patents.google.com/patent/US20090050457
[2] FDA Drug Approval Package – Xarelto. https://www.fda.gov/drugs/resources-information-approved-drugs/xarelto
[3] Bayer. “Patents and Intellectual Property.” https://www.bayer.com/en/patents
[4] Bayer. “Second‑Use Patents for Rivaroxaban.” https://www.bayer.com/en/innovation/second‑use‑patents
[5] DrugPatentWatch. “Generic Challenges for Xarelto.” https://www.drugpatentwatch.com/xarelto